Brief: Homology Medicines Reports Fourth Quarter And Full Year 2021 Results

Q32 Bio

23/03/2022 20:39

March 23 (Reuters) - Homology Medicines Inc  FIXX.O :
    * HOMOLOGY MEDICINES REPORTS FOURTH QUARTER AND FULL YEAR
2021
FINANCIAL RESULTS AND RECENT HIGHLIGHTS
    * Q4 LOSS PER SHARE $0.59
    * RECEIVED $130 MILLION NON-DILUTIVE CAPITAL THAT
SIGNIFICANTLY
EXTENDS CASH RUNWAY
    * Q4 EARNINGS PER SHARE VIEW $-0.59 -- REFINITIV IBES DATA
    * UPDATES GUIDANCE ON PHENIX GENE THERAPY TRIAL FOR PKU
    * PROGRAM UPDATE ON PHEEDIT IS STILL EXPECTED BY YEAR-END
2022
    * HOMOLOGY MEDICINES, ON PHENIX TRIAL, SAYS ESTIMATES MORE
TIME
WILL BE NEEDED TO SUBMIT, RECEIVE FEEDBACK ON PROPOSED CLINICAL
RISK-MITIGATION STRATEGY
    * NOW EXPECTS TO PROVIDE A PROGRAM UPDATE WHEN PATH FORWARD
IS
ESTABLISHED WITH FDA ON PHENIX TRIAL

Source text for Eikon:  ID:nGNX2BCkS0 
Further company coverage:  FIXX.O 

 ((reuters.briefs@thomsonreuters.com;))